Diagnexia
Diagnexia is a cloud-based digital pathology services company that connects hospital laboratories to a global network of GMC-registered subspecialty pathologists for primary diagnostic reporting, secondary consultations, scanning, and clinical-trial support, primarily serving NHS hospitals via a national framework agreement and select international institutions.
- Company typePrivate
- Founded2021
- HeadquartersExeter, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Diagnexia does
Diagnexia is a UK-headquartered digital pathology services company operating a cloud-based platform that connects hospital laboratories to a global network of GMC-registered subspecialty pathologists for primary diagnostic reporting (advertised 3–5 day turnaround, with live wait times showing 1.5 days) and secondary consultations (7–10 day turnaround, 4 days live). The company was founded in 2021, with corporate headquarters in Dublin, Ireland and UK operations centred on CQC-registered accessioning facilities in Exeter (digital accessioning) and Oxford (histology and digital accessioning, UKAS ISO 15189:2022 accredited as of November 2025); additional accessioning centres operate in Naperville, Illinois (US) and Toronto, Ontario (Canada), with primary reporting currently available in the UK and Canada.
The core product is the Diagnexia Hub cloud portal, which handles case onboarding, monitoring, and management with integrated synoptic reporting templates that export into customer laboratory information systems (LIS). Supporting offerings include Scanning Services (client-supplied or Diagnexia-operated scanners at its accessioning centres), Analytix (a sub-brand targeting translational research and clinical trials), External Quality Assurance services aligned to NEQAS schemes, and educational programmes including the Diagnexia Dialogues podcast, an annual Histopathology Symposium, and a Computational Pathology Fundamentals course. The platform also integrates an AI multimodal prostate cancer risk stratification tool through a strategic partnership with Artera.
Diagnexia monetizes per-case pathology reporting fees on a quote-based, multi-year subscription model. Its go-to-market is enterprise sales to NHS hospitals, with distribution via The Countess of Chester Hospital National Framework Agreement for Telepathology, Telepathology and Telemedicine Services — a procurement vehicle that gives any NHS hospital in England transparent, pre-cleared access — supplemented by direct contracts with named NHS Trusts (Derriford Hospital, Bedfordshire Hospitals NHS Foundation Trust, East Sussex Healthcare NHS Trust) and international healthcare institutions in Canada and beyond. The company reports no disclosed revenue or institutional venture funding; the only documented capital inflow is an approximately £50,000 grant from Heart of the South West LEP (via the European Regional Development Fund) in August 2023 to purchase a digital pathology scanner.
Diagnexia firmographics
Firmographics- Name
- Diagnexia
- Legal name
- Diagnexia UK Limited
- Website
- https://diagnexia.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Diagnexia is a cloud-based digital pathology services company that connects hospital laboratories to a global network of GMC-registered subspecialty pathologists for primary diagnostic reporting, secondary consultations, scanning, and clinical-trial support, primarily serving NHS hospitals via a national framework agreement and select international institutions.
- Ownership category
- akta.pro rank
Diagnexia industry classification
Industry- Product category
- Digital Pathology Services
- NAICS
- Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Anatomic Pathology LIS & Digital Pathology Workflow (HLACAMAB)
- akta.pro secondary industries
- Diagnostic/Lab & Imaging Referral Marketplaces (HLALALAG), Pathology Reporting, Synoptic Templates & Cancer Registry Interfaces (HLACAMAJ), Anatomic Pathology (Histopathology & Cytopathology) (HLAFAMAA)
Keywords
Where Diagnexia is headquartered
LocationHeadquarters
- HQ city
- Exeter
- HQ country
- United Kingdom
- HQ region
- Europe
Offices5 records
Markets served
Diagnexia business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Digital Pathology Reporting Services: Provides primary diagnostic reporting (3-5 day turnaround) and secondary consultation services (7-10 day turnaround) for NHS hospitals and healthcare institutions. Revenue generated through service fees for pathology reporting, with transparent pricing for NHS Framework access.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Primary Diagnostic Reporting |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels7 records
Diagnexia product offering
Product offeringCore offering
Diagnexia operates a cloud-based digital pathology platform that connects laboratories to a global network of GMC-registered subspecialty pathologists, delivering primary diagnostic reporting and secondary consultation reports for NHS hospitals and healthcare institutions. The company runs UKAS-accredited histology and digital accessioning centres in the UK and provides scanning services, clinical trial pathology support, and external quality assurance services.
Product overview
Diagnexia is a cloud-based digital pathology platform that functions as a 'global digital pathology department,' connecting laboratories worldwide to an international network of subspecialty pathologists. The core product is the Diagnexia Hub platform, which enables primary diagnostic reporting (3-5 day turnaround) and secondary consultation services (7-10 day turnaround). Supporting services include Scanning Services (with two workflow options: client scanner or Diagnexia scanning), Analytix for clinical trials, and External Quality Assurance services. The company also provides educational offerings including the Diagnexia Dialogues podcast and annual Histopathology Symposium events.
Differentiator
Problem solved
Functional benefit
Products and services
- Digital Pathology Reporting Services Cloud-based delivery of primary diagnostic reports (3-5 day turnaround) and secondary consultation reports (7-10 day turnaround) from a global network of subspecialty pathologists, primarily for NHS hospitals and international healthcare institutions.
- Scanning Services Digital pathology slide scanning services with two workflow options: clients use their own scanners or mail slides to Diagnexia's UK or US accessioning centres for digitization and end-to-end specimen tracking.
- Analytix (Clinical Trials Pathology) Digital pathology services designed for translational research and clinical trials, supporting biopharma sponsors with pathology analysis for drug development studies.
- External Quality Assurance (EQA) Services Independent external quality assurance service providing unbiased feedback on scanner artifacts, color calibration, image quality, and diagnostic accuracy of pathology reports, delivered through the network of expert pathologists.
Quantifiable outcome
- 3-5 day turnaround for primary diagnostic reports
- +3 more outcomes
Companies that use Diagnexia
Customer profileNamed customers4 records
Segments2 records
Ideal customer profiles3 records
Diagnexia technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Diagnexia partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- ArteracoreDiagnexia and Artera partnership brings the first AI multimodal risk stratification tool for localised prostate cancer to the UK. The partnership provides rapid, reliable AI-powered insights to clinicians and patients, combining Diagnexia's digital pathology platform with Artera's AI technology.
- Countess of Chester Hospital NHS Foundation TrustcoreDiagnexia is a supplier on The Countess of Chester Hospital National Framework Agreement for Teleradiology, Telepathology and Telemedicine Services, enabling any NHS hospital to access Diagnexia services through this framework.
- NHS Trusts (General)coreNHS hospitals including Bedfordshire Hospitals NHS Foundation Trust, East Sussex Healthcare NHS Trust, and Derriford Hospital access Diagnexia services for backlog management, primary reporting, and specialist consultations.
- iCAIRD ProgrammeminorInnovation UK funded iCAIRD programme involving digital pathology deployment. Dr Gareth Bryson, Consultant Pathologist at Diagnexia, is Honorary Senior Lecturer at University of St Andrews contributing to this programme.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Diagnexia competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Diagnexia social profiles
Digital presenceDiagnexia compliance and trust
Trust signalCompliance4 records
Diagnexia financial estimates
Financial estimateRevenue estimate
Valuation estimate
Diagnexia leadership team
Management profileNumber of profiles
Profiles2 records
Diagnexia funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Diagnexia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Diagnexia
What does Diagnexia do?
Diagnexia operates a cloud-based digital pathology platform that connects laboratories to a global network of GMC-registered subspecialty pathologists, delivering primary diagnostic reporting and secondary consultation reports for NHS hospitals and healthcare institutions. The company runs UKAS-accredited histology and digital accessioning centres in the UK and provides scanning services, clinical trial pathology support, and external quality assurance services.
Is Diagnexia a public or private company?
Diagnexia is a private company. It is classified as unknown and is currently operating.
When was Diagnexia founded?
Diagnexia was founded in 2021. It employs 11 to 50 people.
Where is Diagnexia based?
Diagnexia is headquartered in Exeter, United Kingdom, in the Europe region.
How does Diagnexia make money?
One revenue line is on record: digital Pathology Reporting Services.
Does Diagnexia have an API?
No public API is recorded for Diagnexia.
What industry is Diagnexia in?
Diagnexia's product category is Digital Pathology Services. Its primary akta.pro industry code is HLACAMAB, Anatomic Pathology LIS & Digital Pathology Workflow, with a secondary code of HLALALAG, Diagnostic/Lab & Imaging Referral Marketplaces. Its NAICS code is 621511 and its SIC code is 8071.